Table 1d:

Clinical information on HIV-infected ART-treated participants included in the colon biopsy study cohort

ID symbol	Age (years)	Sex	CD4*	CD8*	CD4:CD8 ratio	Plasma viral load#	Time of infection (months)	ART	Time on ART (months)
HIV+ART #13	51	M	175	1,100	0.16	<40	231	Triumeq	204
HIV+ART #14	50	M	453	729	0.62	<40	233	Truvada Viramune	204
HIV+ART #15	54	M	895	1,023	0.87	<40	224	Norvir Reyataz Truvada	192
HIV+ART #16	67	M	314	793	0.40	<40	244	Darunavir Etravirine Dolutegravir Norvir	176
HIV+ART #17	56	M	786	1,813	0.43	<40	240	Isentress Truvada	72
HIV+ART #18	58	M	718	1,079	0.67	<40	305	Tivicay Kivexa	204
HIV+ART #19	55	M	513	1,095	0.47	<40	192	Kivexa Isentress	N/A
HIV+ART #20	56	M	288	407	0.71	<40	216	Stribild	216

ID, participant identity; M, male;

^*, cells/µl;

#, HIV-RNA copies/ml; N/A, data not available;

Note: HIV+ART#2 and HIV+ART#16, as well as HIV+ART#6 and HIV+ART#17 represent the same individual, with blood collected at different time points.